A phase II study of EDP-305 in patients with Non-alcoholic steatohepatitis (NASH)

Trial Profile

A phase II study of EDP-305 in patients with Non-alcoholic steatohepatitis (NASH)

Planning
Phase of Trial: Phase II

Latest Information Update: 12 Jan 2017

At a glance

  • Drugs EDP 305 (Primary)
  • Indications Non-alcoholic steatohepatitis
  • Focus Therapeutic Use
  • Most Recent Events

    • 12 Jan 2017 New trial record
    • 06 Jan 2017 According to an Enanta Pharmaceuticals media release, the company expects to initiate this study in early 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top